Kanker ati
Dina taun-taun ayeuna, insiden sareng mortalitas kanker ati di dunya parantos luhur. Nagara-nagara berkembang kira-kira 50% kasus kanker ati anyar unggal taun, sareng tingkat insiden tumor ganas nyaéta kaopat. Sanajan kitu, lolobana penderita kanker ati pakait sareng sirosis, atawa paling penderita geus ngahontal tahap canggih dina waktu diagnosis, sarta ngeunaan 20% -30% pasien bisa meunang kasempetan resection bedah.
Aya seueur pangobatan pikeun kanker ati, tapi kanker hépatik sesah diubaran
Surgery is the only way to cure liver cancer, and only early liver cancer has this opportunity. In addition to surgery, local treatment methods include surgery, transcatheter arterial chemoembolization, percutaneous radiofrequency ablation, and radiation therapy; systemic treatment includes chemotherapy, targeted therapy, and immunotherapy.
With the increasing number of treatments for liver cancer in recent years, precision surgical treatment combined with systemic targeted therapy (sorafenib, lervatinib, regorafenib, cabozantinib and ramozumab) and immunotherapy (Pimumab, Navumab), individualized combination therapy for patients, the treatment effect of advanced liver cancer is greatly improved.
Sacara klinis, sakitar 90% pasien kanker ati gaduh riwayat hépatitis B, 5% -8% pasien kanker ati kainfeksi hépatitis C, sareng sakitar 3% pasien aya hubunganana sareng sirosis disababkeun ku alkoholisme kronis, ati lemak. , jeung kasakit nu patali kasakit ati otoimun.
Clinically, the curse of the three-step model (HBV-cirrhosis-liver kangker) has always threatened many domestic liver cancer patients, making many cutting-edge treatment methods unable to improve the current status of liver cancer treatment. New therapies are urgently needed to solve the hepatitis B-related perlakuan kanker ati.
Ngalengkepan sél T ku antigén khusus pakarang anyar
Panaliti di Rumah Sakit Nasional Duke-Singapura mendesain Sél T spésifik virus Hépatitis B pikeun ngubaran karsinoma hépatoselular tipe hépatitis B, jinis kanker ati anu umum di Asia.
Researchers have individualized T cells to make T cells specific to patients. I think this is a CAR-T-like cellular immunotherapy, which is to advance specific antigens of tumor cells by technical means to activate them. T cells, after activated T cells are infused back into the body, it is like updating the weapon scouts to precisely attack cancer cells.
Tim éta suksés ngarawat dua pasien kalayan cangkok ati kalayan sél-T khusus, dua di antarana sateuacana katépaan kanker ati anu disababkeun ku virus hépatitis B, sareng ayeuna parantos kambuh saatos cangkok ati. Saatos terapi sél T khusus, salah sahiji pasien ningali panurunan dina fokus tumor.
Target antigen nyaéta HBV-DNA
Dina terapi pribadi, panalungtik dianalisis pola integrasi HBV-DNA husus dina sél kanker unggal penderita kanker ati, lajeng disaring, dirancang jeung ngolah sél T individualized, lajeng dirawat. Leuwih ti 20 transfusi sél T anu hasil dipigawé dina dua penderita cangkok ati, sarta sél T direkayasa ieu bisa ngancurkeun tumor.
Panalungtik senior, Antonio Bertoletti ceuk: Komponén gén HBV-DNA terpadu bisa ngaktipkeun sél T HBV-spésifik fungsi sarta maéhan sél kanker ati hépatitis-spésifik tanpa mangaruhan sél cageur lianna. Henteu aya réaksi ngarugikeun anu aya hubunganana sareng perlakuan, sareng metastasis jauh kanker ati dina hiji pasien ogé ngagaduhan réduksi anu signifikan.
kanker paru caused by chronic hepatitis B infection accounts for 80% of all liver cancers in Asian lung cancer, and the treatment prognosis is not ideal. Especially in patients with liver cancer recurrence after liver transplantation, treatment options are more limited.
Terapi sél T spésifik anu dikembangkeun ku National Medical College of Singapore tiasa ningkatkeun kasalametan sareng kualitas kahirupan pasien tinangtu ieu. Terapi sél CAR-T mangrupakeun harepan anyar pikeun ngéléhkeun kanker dina mangsa nu bakal datang!
Terapi sél CAR-T nyaeta Chimeric Antigen Receptor T-Cell Immunotherapy. Ieu mangrupikeun jinis terapi sasaran anu énggal pikeun ngubaran tumor. Dina taun-taun ayeuna, éta parantos ngahontal hasil anu saé dina pengobatan tumor klinis ngaliwatan optimasi sareng perbaikan. Éta pisan ngajangjikeun, akurat, gancang, éfisién, sareng kamungkinan pikeun ngubaran kanker. Imunoterapi tumor anyar.
Anjeun panginten hoyong maca: Terapi T-Cell mobil di India
Terapi CAR-T nyaéta métode pengobatan kanker anu geus kahontal breakthroughs signifikan dina taun panganyarna, sarta geus disatujuan ku departemén internasional relevan pikeun pamakéan klinis dina pengobatan tumor hematological. Salaku tambahan, uji klinis terapi sél CAR-T pikeun tumor padet aya dina ayunan pinuh.
